These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 25449686)
41. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Tanaka R; Kimura S Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691 [TBL] [Abstract][Full Text] [Related]
45. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733 [TBL] [Abstract][Full Text] [Related]
46. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India. Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669 [No Abstract] [Full Text] [Related]
47. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753 [TBL] [Abstract][Full Text] [Related]
48. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740 [TBL] [Abstract][Full Text] [Related]
49. Detection of Baer C; Meggendorfer M; Haferlach C; Kern W; Haferlach T Haematologica; 2022 Feb; 107(2):562-563. PubMed ID: 34758608 [No Abstract] [Full Text] [Related]
51. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973 [TBL] [Abstract][Full Text] [Related]
52. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. Baccarani M; Soverini S; De Benedittis C Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074 [TBL] [Abstract][Full Text] [Related]
53. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well? Andolina JR Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547 [No Abstract] [Full Text] [Related]
54. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Cao ZX; Liu JJ; Zheng RL; Yang J; Zhong L; Xu Y; Wang LJ; Zhang CH; Wang BL; Ma S; Wang ZR; Xie HZ; Wei YQ; Yang SY Leukemia; 2012 Aug; 26(8):1892-5. PubMed ID: 22402607 [No Abstract] [Full Text] [Related]
55. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884 [TBL] [Abstract][Full Text] [Related]
56. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906 [TBL] [Abstract][Full Text] [Related]